Arcturus Therapeutics (ARCT) Tops Q2 EPS by 38c
Tweet
Share
E-mailGet Alerts ARCT Hot Sheet
Join SI Premium – FREE
Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($0.64), $0.38 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $49.86 million versus the consensus estimate of $32.26 million.
For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
- Culp, Inc. (CULP) Misses Q4 EPS by 12c
- Activist group calls for Genesco director to resign over credential claims
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
